Cloverleaf Bio · Seed
Scientist, Oligonucleotide Synthesis
Boston, MA
Posted 4 days ago· Nov 16

Biopharma, Biotechnology, Genetics
Cloverleaf Bio raised $33M in a Seed announced on Sep 8, 2026, led by Eli Lilly, Draper Associates, AbbVie, Mission BioCapital, Boehringer Ingelheim Venture Fund. Since then it has posted 3 roles (3 still open), the first 27 days after it. Another 1 open role was posted before the announcement. With 4 open roles it is hiring more than 28% of the 147 Seed startups on JustBacked (median: 6). In total it has raised $33M over 2 rounds from 7 investors.
From Cloverleaf Bio's own hiring system, by posting date. Tracked since Oct 1, 2026; roles that closed before then aren't counted.
Cloverleaf Bio develops an RNA therapeutic platform for oncology.
The bet: a new class of RNA medicines could become a core oncology tool, and Cloverleaf Bio, a New Haven biotech, is building the platform behind it. If it works, oncology gets a new kind of medicine that Eli Lilly, AbbVie and Boehringer Ingelheim already want a piece of. Its $33M seed beats 90% of its stage's rounds, and a team of 1-10 has room for early hires to shape the science.
JustBacked's take, based on Cloverleaf Bio's own site and its funding and hiring data.
Hiring velocity
Where they're hiring
Cloverleaf Bio · Seed
Boston, MA
Posted 4 days ago· Nov 16
Cloverleaf Bio · Seed
Boston, MA
Posted 38 days ago· Oct 13
Cloverleaf Bio · Seed
Boston, MA
Posted 46 days ago· Oct 5
Cloverleaf Bio · Seed
Boston, MA
Posted 75 days ago· Sep 7
Source: cloverleaf-bio.breezy.hr, checked daily.